Team

Juan-Pablo is a partner at APVC in Santa Cruz, CA. He represents APVC on the Boards of Cala Health, Exo Imaging, Neuspera Medical, Presidio Medical, Saluda Medical, SetPoint Medical, Onc.ai and previously CVRx (NASDAQ: CVRX). He was a founding team member and investor at Lightstone Ventures, and an investor at Morgenthaler Ventures, where he was a Board observer at Ardian (acq. by Medtronic), Twelve (acq. by Medtronic), Nuvaira, Cabochon Aesthetics (acq. by Ulthera/Merz), and Miramar Labs (acq. by Sientra).

Prior to investing, Juan-Pablo led efforts in R&D and Strategy in Medtronic’s CardioVascular Division. He was named “Medtronic Inventor of The Year”. Subsequently, he was on the Global Brand Strategy team at Eli Lilly within the Cardiovascular business.

Juan-Pablo earned an MBA and an M.S. in Electrical Engineering from Stanford University, and a B.S. in Electrical Engineering from the University of Massachusetts. He serves on Stanford’s Neuroscience Institute Oversight Committee, the Advisory Board for UCSF’s Rosenman Institute, the Investor Advisory Committee of AdvaMed, and is a founding Board Member of SomosVC which is dedicated to increasing the representation and advancement of Latino and Latina VCs across industry verticals. Juan-Pablo previously served eight years on the Board of InnerCity Weightlifting, a non-profit reducing youth violence and incarceration rates by fostering social inclusion and economic mobility. He played Division I men’s lacrosse at the University of Massachusetts, serves on the Board of USA Lacrosse since 2023, and is originally from Puerto Rico.

Imran is a partner at APVC in Cambridge, MA. He represents APVC on the boards of Alpheus Medical, MicroTransponder, Neuspera Medical and SetPoint Medical.

Before joining Action Potential, Imran was in the Worldwide Business Development group of GSK working in a variety of business development and investing roles. Imran led the establishment of and headed up the Investment Management practice. The group was tasked with accessing technology and innovation external to GSK by making and managing investments in life science venture capital funds as limited partners and direct investments in biotechs made as part of GSK’s R&D collaborations.

Imran received his bachelor’s degree in finance from Concordia University in his native Canada and has trained as a Chartered Accountant. He serves on the Advisory Board of the Harvard HealthTech Fellowship and as a Mentor for the Neuro stream at the Creative Destruction Labs at the University of Toronto. Imran is a member of the Board of Trustees and the Investment and Finance Committees of the Hartford International University for Peace and Religion and is a member of the Board of Ambassadors of the Brooke Charter School in Boston.

Suraj Mudichintala is a senior associate at APVC in Santa Cruz, CA. He represents APVC on the Boards of Alpheus Medical and Onc.ai. He was previously an investor at Arboretum Ventures, where he served as a Board observer at Allay Therapeutics, Avation Medical, Francis Medical, Health Scholars, Koya Medical, and RareCyte. Prior to investing, Suraj was an associate with L.E.K. Consulting, a global strategy consulting firm. While at L.E.K., Suraj completed ~20 engagements predominantly for life sciences and private equity clients.

Suraj graduated cum laude with a B.S. in Finance and Analytics from Boston College. Suraj previously served on the Michigan Translational Research and Commercialization (MTRAC) Oversight Committee for Medical Devices, where he provided guidance to Michigan higher education researchers on transitioning their early stage products to the private sector for commercialization.

Rami is currently Chairman and CEO of Arcellx and an Advisor at APVC in Palo Alto, Ca. He supports APVC in evaluating and executing new investments and serves as an advisor to select APVC portfolio companies. Prior to joining APVC, Rami was President and CEO of Nevro where he grew the company from a thirty person start up to nearly one thousand person public company approaching $400M in revenue. Nevro's value increased over 15x and the stock was valued over 300% above IPO pricing during Rami's tenure. In this role, Rami was recognized as a top CEO in the U.S., one of the top CEOs for women and diversity, and is a recipient of the Bill Campbell Award by Watermark, a leading women's organization, for his influence, impact, and advocacy in promoting women and women's issues. Prior to Nevro, Rami was an investor with Johnson and Johnson Development Corporation where he led Nevro's Series B financing, sat on over 10 Boards including Nevro's and worked on strategic initiatives and M&A for J&J.

Rami began his career as a Design Engineer at Advanced Neuromodulation Systems. Rami earned a B.S. in Electrical and Computer Engineering from Rutgers University and an MBA from the Wharton School of the University of Pennsylvania. Rami serves as a start up advisor, a guest lecturer, and as a judge for the EY Entrepreneur of the Year program.